BioSpace News Archive

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta®, the new in-line, blood-gas monitoring system integrated into the market-leading S5® heart-lung machine (HLM)

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (“FDA”) supporting the Company’s development strategy to submit an initial new drug application (“IND”) application for a Phase 2 study of Trappsol

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit

We are proud to share that the unaudited number of tests processed by the ScreenPro team for the month of March were over 30,000.

In addition, the consistency between the Company’s in vitro and in vivo data is a substantial validation for Mindset’s in vitro screening protocols.

TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation of clinical trials, announces the addition of life sciences veteran Steve Holtzman as a key strategic advisor

Presidio Medical, Inc. , a clinical-stage medical device company developing a neuromodulation platform, today announced that Katherine H. Neuenfeldt has joined the Executive Team as Vice President, Marketing.

Today, Bayer announced that two of its top Pharmaceutical executives will take on new leadership roles within the division to advance its position in key therapeutic areas.

ZAP Surgical Announces Future Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich, Germany European CyberKnife Center to be Among the First Providers in the World to Offer the Latest Advance in Gyroscopic Radiosurgery

- Efficacy and Product Integration Testing Slated for Completion in Fall 2021 - Upon FDA Clearance the WellnessPro POD ™ Device Could Emerge as a Leading Chronic Pain drug-free choice to Opioids for Mass Market Retail Customers.